TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9859596

Group type: EXPERIMENTAL
Intervention: Lipidic matrix of Gelucire 44/14
Number of subjects: 8

Group type: COMPARATOR
Intervention: Commercially available tablet (control)
Number of subjects: 8
Study: 7889183

Group type: EXPERIMENTAL
Intervention: Oral TRH (40 mg, 12 hourly) plus metoclopramide (10 mg, 8 hourly)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Oral TRH (40 mg, 12 hourly) plus placebo (one capsule, 8 hourly)
Number of subjects: 7
Study: 2231049

Group type: EXPERIMENTAL
Intervention: Preventive care services provided by physicians
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: U.S. Preventive Services Task Force's guide to clinical preventive services
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comprehensive care including prevention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: External pressures affecting physician-patient relationship
Number of subjects: 0
Study: 857102

Group type: EXPERIMENTAL
Intervention: Phone reminder call
Number of subjects: 98

Group type: COMPARATOR
Intervention: No call (Control)
Number of subjects: 98
Study: 30538278

Group type: EXPERIMENTAL
Intervention: Weight loss intervention (specifics not provided)
Number of subjects: 219
Study: 29879520

Group type: EXPERIMENTAL
Intervention: 2 liters of normal saline (NS)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: 2 liters lactated Ringer's (LR)
Number of subjects: 157

Group type: COMPARATOR
Intervention: No IV fluid (noIVF)
Number of subjects: 157
Study: 27574260

Group type: EXPERIMENTAL
Intervention: 20 ml of 0.375% ropivacaine plus tramadol 50 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 20 ml of 0.375% ropivacaine plus tramadol 100 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: No preoperative femoral nerve block (control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Femoral nerve block with ropivacaine (no tramadol)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Femoral nerve block (all groups)
Number of subjects: 60
Study: 25048048

Group type: EXPERIMENTAL
Intervention: Hybrid fixation (1 u‐HA/PLLA plate and 4 mono‐cortical screws and a bi‐cortical screw in each side)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Conventional fixation (1 u‐HA/PLLA plate and 4 mono‐cortical screws in each side)
Number of subjects: 66
Study: 22949150

Group type: EXPERIMENTAL
Intervention: Gemcitabine (1,250 mg/m² days 1 and 8 of a 3-week cycle)
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg/day)
Number of subjects: 464

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Second-line pemetrexed (500 mg/m² once every 21 days)
Number of subjects: 464
Study: 20594347

Group type: EXPERIMENTAL
Intervention: Work-directed intervention consisting of 4 meetings with a nurse, 1 meeting with an occupational physician and supervisor, and letters from the treating physician to enhance communication.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 0
Study: 17604912

Group type: EXPERIMENTAL
Intervention: 40 mg cortisol (oral administration)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (oral administration)
Number of subjects: 20
Study: 16100331

Group type: EXPERIMENTAL
Intervention: Culturally competent dietary self‐management intervention consisting of 4 weekly classes in low‐fat dietary strategies, 5 monthly peer‐professional group discussions, and weekly telephone follow‐up
Number of subjects: 97

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Culturally competent dietary self‐management intervention
Number of subjects: 97
Study: 12859585

Group type: EXPERIMENTAL
Intervention: Oral eletriptan 40 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral eletriptan 80 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral sumatriptan 50 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral sumatriptan 100 mg
Number of subjects: 0
Study: 10370679

Group type: EXPERIMENTAL
Intervention: 1 g Ceftriaxone
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: 2 g Ceftriaxone
Number of subjects: 82

Group type: COMPARATOR
Intervention: Ceftriaxone (1 g or 2 g)
Number of subjects: 82
Study: 8958612

Group type: EXPERIMENTAL
Intervention: Warfarin (Coumadin) therapy with guidelines for initiation, monitoring, and reversal
Number of subjects: 0
Study: 1515384

Group type: COMPARATOR
Intervention: 1 ml physiologic saline
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 0.2 ml (1 mg) 0.5% phenylephrine plus 0.8 ml normal saline
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 0.4 ml phenylephrine plus 0.6 ml normal saline
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 0.6 ml phenylephrine plus 0.4 ml normal saline
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 0.8 ml phenylephrine plus 0.2 ml normal saline
Number of subjects: 100
Study: 6093522

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 1 g daily
Number of subjects: 84

Group type: COMPARATOR
Intervention: Cefazolin 3 to 4 g daily
Number of subjects: 84
Study: 30449536

Group type: COMPARATOR
Intervention: Intramuscular dexamethasone at 10 mg
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Intramuscular methylprednisolone acetate at 160 mg
Number of subjects: 220
Study: 27734464

Group type: EXPERIMENTAL
Intervention: Eltrombopag 25 mg once daily
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study: 25526812

Group type: EXPERIMENTAL
Intervention: Multi-dimensional family therapy (MDFT)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 5
Study: 23826842

Group type: EXPERIMENTAL
Intervention: Decision aid (DA) DVD
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard information (control group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Brachytherapy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Radical prostatectomy (RP)
Number of subjects: 30
Study: 20883990

Group type: EXPERIMENTAL
Intervention: Plasma preptin levels in women with PCOS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (women without PCOS)
Number of subjects: 0
Study: 19182155

Group type: EXPERIMENTAL
Intervention: Trihexyphenidyl
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 17443731

Group type: EXPERIMENTAL
Intervention: Combined brief psychosexual intervention (CBPI)
Number of subjects: 20
Study: 15295690

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study: 12566370

Group type: EXPERIMENTAL
Intervention: Enalaprilat (5 micro g/min)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Enalaprilat (5 micro g/min) with bradykinin (100 ng/min)
Number of subjects: 24

Group type: COMPARATOR
Intervention: HOE 140 (100 microg/kg intravenously)
Number of subjects: 24
Study: 10356958

Group type: EXPERIMENTAL
Intervention: LA-1 oncoprotein
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: HPV 16 E2
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Recombinant vaccinia virus HSV-2 gD protein
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Correlation of LA-1 and HPV16 E2 seropositivity
Number of subjects: 46
Study: 7972348

Group type: EXPERIMENTAL
Intervention: Propentofylline at 0.9 g/d
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study: 2570005

Group type: EXPERIMENTAL
Intervention: Famotidine (40 mg at night)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Cimetidine (800 mg at night)
Number of subjects: 119
Study: 16801

Group type: EXPERIMENTAL
Intervention: triazolam 0-5 mg
Number of subjects: 104

Group type: COMPARATOR
Intervention: triazolam 0-25 mg
Number of subjects: 104
Study: 31663683

Group type: EXPERIMENTAL
Intervention: Competing risk nomogram using the model of the worse characteristics
Number of subjects: 10319

Group type: EXPERIMENTAL
Intervention: Competing risk nomogram using the model of bilateral tumors
Number of subjects: 10319

Group type: EXPERIMENTAL
Intervention: Competing risk nomogram using the model of worse tumor
Number of subjects: 10319

Group type: EXPERIMENTAL
Intervention: Competing risk nomogram using the model of first tumor
Number of subjects: 10319

Group type: EXPERIMENTAL
Intervention: Competing risk nomogram using the model of second tumor
Number of subjects: 10319

Group type: EXPERIMENTAL
Intervention: Net reclassification index for 3-year and 5-year survival
Number of subjects: 10319

Group type: EXPERIMENTAL
Intervention: Calibration curves
Number of subjects: 10319
Study: 27182765

Group type: EXPERIMENTAL
Intervention: Workplace mindfulness training (WMT)
Number of subjects: 113
Study: 25979316

Group type: EXPERIMENTAL
Intervention: Take‐N‐Slide(™)
Number of subjects: 53480

Group type: EXPERIMENTAL
Intervention: RxTimerCap(™)
Number of subjects: 53480

Group type: EXPERIMENTAL
Intervention: Standard pillbox
Number of subjects: 53480

Group type: COMPARATOR
Intervention: Control group (no device)
Number of subjects: 53480
Study: 23668675

Group type: EXPERIMENTAL
Intervention: Oat-enriched diet
Number of subjects: 27

Group type: COMPARATOR
Intervention: Standard dietary advice
Number of subjects: 27
Study: 20636429

Group type: EXPERIMENTAL
Intervention: Nebulized 3% hypertonic saline (HS)
Number of subjects: 126

Group type: COMPARATOR
Intervention: 0.9% normal saline (NS)
Number of subjects: 126
Study: 19629539

Group type: EXPERIMENTAL
Intervention: SCION program (advisory consultation, optimizing emesis prophylaxis, nutrition counseling, relaxation)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Standard antiemetic treatment and standard care (Control group)
Number of subjects: 208
Study: 17432400

Group type: EXPERIMENTAL
Intervention: Variolink 2/Syntac Classic (group 1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bifix DC/Solobond Plus (group 2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Calibra/Prime & Bond NT combinations (group 3)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Zinc-phosphate cement (control group 4)
Number of subjects: 40
Study: 15142023

Group type: EXPERIMENTAL
Intervention: Creatine powder in solution (CP) - 20 g.day(‐1) x 6 days
Number of subjects: 11

Group type: COMPARATOR
Intervention: Creatine serum (CS) - 5 ml.day(‐1) x 6 days
Number of subjects: 11
Study: 11701194

Group type: EXPERIMENTAL
Intervention: 4 standard units of alcohol (40 g) under fasting conditions
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 4 standard units of alcohol (40 g) after food consumption
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo under fasting conditions
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo after food consumption
Number of subjects: 7
Study: 9683155

Group type: EXPERIMENTAL
Intervention: Nidek ARK-900 objective refractor
Number of subjects: 100

Group type: COMPARATOR
Intervention: Retinoscopy
Number of subjects: 100
Study: 7995664

Group type: EXPERIMENTAL
Intervention: Constrictive pericarditis
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Post-operative normal hemodynamics (n = 12)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Post-operative persisting hemodynamic abnormality (n = 6)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Restrictive cardiomyopathy
Number of subjects: 33

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 33
Study: 1673942

Group type: EXPERIMENTAL
Intervention: Spironolactone (Aldactone)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (Gestapuran)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 365544

Group type: EXPERIMENTAL
Intervention: Timolol and bendrofluazide (once daily dosage)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Timolol and bendrofluazide (twice daily dosage)
Number of subjects: 44
Study: 30873703

Group type: EXPERIMENTAL
Intervention: Fluorescence angiography (FA) during IPAA surgery
Number of subjects: 32

Group type: COMPARATOR
Intervention: Historical controls (no FA)
Number of subjects: 32
Study: 28093841

Group type: EXPERIMENTAL
Intervention: Valsartan (160 mg daily)
Number of subjects: 9306

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9306
Study: 26229148

Group type: EXPERIMENTAL
Intervention: SPECT/CT
Number of subjects: 1508

Group type: COMPARATOR
Intervention: Planar Imaging (PI)
Number of subjects: 1508
Study: 23500262

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg
Number of subjects: 7817

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 5 mg
Number of subjects: 7817

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7817

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (both doses)
Number of subjects: 7817
Study: 21447465

Group type: EXPERIMENTAL
Intervention: Visual scanning
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Mental practice
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study: 19318434

Group type: EXPERIMENTAL
Intervention: C allele of the PARP1 rs1136410 variant
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Homozygous for the G allele of the PRKDC rs7003908 variant
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Haplotype modeling of ERCC2 rs13181, ERCC1 rs3212986, and GLTSCR1 rs1035938
Number of subjects: 1000
Study: 17453555

Group type: EXPERIMENTAL
Intervention: Carers Assessment of Difficulties Index (CADI)
Number of subjects: 232
Study: 15502027

Group type: EXPERIMENTAL
Intervention: isoflurane 0.6% + air + O(2) 30%
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: propofol 120 microg . kg(‐1) . min(‐1) + air + O(2) 30%
Number of subjects: 12

Group type: COMPARATOR
Intervention: isoflurane 0.4% + N(2)O 70% + O(2) 30%
Number of subjects: 12

Group type: COMPARATOR
Intervention: isoflurane 0.6% + N(2)O 70% + O(2) 30%
Number of subjects: 12
Study: 11201624

Group type: EXPERIMENTAL
Intervention: Home rehabilitation
Number of subjects: 81

Group type: COMPARATOR
Intervention: Routine rehabilitation
Number of subjects: 81
Study: 8959084

Group type: EXPERIMENTAL
Intervention: Oral prednisolone (20 mg) administered prior to and 16 hours after depot bromocriptine (50 or 100 mg) injection
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo administered prior to and 16 hours after depot bromocriptine (50 or 100 mg) injection
Number of subjects: 21
Study: 1488563

Group type: EXPERIMENTAL
Intervention: Maximal inspiratory pressure (PImax)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Maximal expiratory pressure (PEmax)
Number of subjects: 20
Study: 3893730

Group type: EXPERIMENTAL
Intervention: Naproxen (initial dose 750 mg, additional 250-500 mg as needed, max 5 tablets in 24h)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 31610549

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (20 mg/d or 15 mg/d, according to renal function)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Dose‐adjusted vitamin K antagonists (VKAs)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 190
Study: 29758152

Group type: EXPERIMENTAL
Intervention: OC15AB mouthwash
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 40
Study: 27321312

Group type: EXPERIMENTAL
Intervention: Metformin + DPP4 inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metformin + insulin-secretagogues (IS)
Number of subjects: 0
Study: 24382299

Group type: EXPERIMENTAL
Intervention: Combined parent-student intervention
Number of subjects: 2937

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2937
Study: 22128201

Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg loading dose, 75 mg/d for 4 days) with standard breakfast
Number of subjects: 72

Group type: COMPARATOR
Intervention: Clopidogrel (300 mg loading dose, 75 mg/d for 4 days) in fasted state
Number of subjects: 72
Study: 18083064

Group type: EXPERIMENTAL
Intervention: Wetsuit (WS)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Swimsuit (SS)
Number of subjects: 12
Study: 17484581

Group type: EXPERIMENTAL
Intervention: Ambiguous request interpretation with prior verbal and physical contact with the ball
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stable cues to the ball's spatial location
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conflict between spatial information and color cue
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition with mere presence of the experimenter
Number of subjects: 0
Study: 16326875

Group type: EXPERIMENTAL
Intervention: Stainless steel/Enduron articulation
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Stainless steel/Hylamer cup
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Zirconium oxide ceramic/Enduron
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Zirconium oxide ceramic/Hylamer
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group (stainless steel/Hylamer vs zirconium oxide ceramic/Hylamer)
Number of subjects: 114
Study: 12494713

Group type: EXPERIMENTAL
Intervention: Atraumatic restorative treatment (ART) using glass-ionomer (GI) and compomer materials
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Minimal intervention treatment (MIT) using glass-ionomer (GI) and compomer materials
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Pain assessment during restoration procedures
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Follow-up of restorations after one year
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Success of restorations per region
Number of subjects: 401
Study: 9535153

Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg daily)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg daily)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Enalapril and Losartan
Number of subjects: 8
Study: 7710392

Group type: EXPERIMENTAL
Intervention: 6.00-mm ablation diameter
Number of subjects: 80

Group type: COMPARATOR
Intervention: 5.00-mm ablation diameter
Number of subjects: 80
Study: 2533042

Group type: EXPERIMENTAL
Intervention: Felodipine (5 mg twice daily for 19 patients, 10 mg twice daily for 2 patients)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 21
Study: 335882

Group type: EXPERIMENTAL
Intervention: Vegetable-protein diet
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Vegetable-protein diet with lactulose
Number of subjects: 3

Group type: COMPARATOR
Intervention: Animal-protein diet
Number of subjects: 3
Study: 31813636

Group type: EXPERIMENTAL
Intervention: Accelerated Partial Breast Irradiation (APBI) delivered as 34 Gy of brachytherapy or 38.5 Gy of external beam radiation therapy in 10 fractions over 5 treatment days within an 8-day period.
Number of subjects: 4216

Group type: COMPARATOR
Intervention: Whole-breast irradiation delivered in 25 daily fractions of 50 Gy over 5 weeks, with or without a supplemental boost to the tumour bed.
Number of subjects: 4216

Group type: EXPERIMENTAL
Intervention: APBI
Number of subjects: 4216

Group type: COMPARATOR
Intervention: Whole-breast irradiation
Number of subjects: 4216
Study: 29267556

Group type: EXPERIMENTAL
Intervention: Abdominal computer tomography (CT)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Isolated serial clinical exam (SCE)
Number of subjects: 66
Study: 26185423

Group type: EXPERIMENTAL
Intervention: Sustained-release (SR) formulation of cilostazol 200 mg every 24 hours
Number of subjects: 30

Group type: COMPARATOR
Intervention: Immediate-release (IR) formulation of cilostazol 100 mg every 12 hours
Number of subjects: 30
Study: 23448818

Group type: EXPERIMENTAL
Intervention: Delayed administration of rabbit antithymocyte globulin
Number of subjects: 231

Group type: COMPARATOR
Intervention: Rabbit antithymocyte globulin (control group)
Number of subjects: 231
Study: 21063786

Group type: EXPERIMENTAL
Intervention: Acute migraine treatment
Number of subjects: 330
Study: 19623197

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (20,000 IU for infants ≤1 year; 45,000 IU for infants >1 year)
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (20 mg daily)
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: Combined vitamin A-zinc supplement
Number of subjects: 584

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 584
Study: 17236889

Group type: EXPERIMENTAL
Intervention: ER metoprolol 0.2 mg/kg
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: ER metoprolol 1.0 mg/kg
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: ER metoprolol 2.0 mg/kg
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 15590583

Group type: EXPERIMENTAL
Intervention: Prinomastat
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study: 11115719

Group type: EXPERIMENTAL
Intervention: Engerix‐B (10 microg hepatitis B surface antigen)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recombivax (5 microg hepatitis B surface antigen)
Number of subjects: 0
Study: 9306340

Group type: EXPERIMENTAL
Intervention: Intensified antihypertensive treatment (felodipine, metoprolol, or ramipril)
Number of subjects: 39
Study: 8374373

Group type: EXPERIMENTAL
Intervention: Aspirin and non-steroidal anti-inflammatory drugs
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory drugs prescribed for longer than five years
Number of subjects: 476

Group type: COMPARATOR
Intervention: Paracetamol or other drugs
Number of subjects: 476
Study: 3737444

Group type: EXPERIMENTAL
Intervention: 20 I.U. lysine‐vasopressin
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 31135283

Group type: EXPERIMENTAL
Intervention: Standard tube
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reversed tubes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reversed laryngoscope blades
Number of subjects: 0
Study: 29274179

Group type: EXPERIMENTAL
Intervention: Single motivational interview (MI)
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Single motivational interview plus cognitive‐behavioural self‐help workbook (MI + W)
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Single motivational interview plus workbook plus four booster follow‐up telephone interviews (MI + W + B)
Number of subjects: 462

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 462
Study: 27891769

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 24
Study: 26195963

Group type: EXPERIMENTAL
Intervention: Duloxetine therapy with pelvic floor exercise (Group A)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Pelvic floor exercise only (Group B)
Number of subjects: 58